Cite

HARVARD Citation

    McKenzie, A. et al. (2022). A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab. Clinical and translational science. 15 (3), pp. 626-637. [Online]. 
  
Back to record